Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295301 | 1.00 | LPL (0.32) | LPLLIPGEGFRLIPE | |
| SCHEMBL23295300 | 1.00 | LPL (0.32) | LPLLIPGEGFRLIPE | |
| SCHEMBL31467992 | 1.00 | LPL (0.32) | LPLLIPGEGFRLIPE | |
| SCHEMBL29691149 | 0.86 | LPL (0.36) | LPLLIPGLIPE | |
| SCHEMBL18865597 | 0.86 | LPL (0.36) | LPLLIPGLIPE | |
| SCHEMBL25794227 | 0.82 | — | — | |
| SCHEMBL31184347 | 0.80 | LPL (0.34) | LPLLIPGLIPE | |
| SCHEMBL17841555 | 0.80 | LPL (0.34) | LPLLIPGLIPE | |
| SCHEMBL18865928 | 0.80 | LPL (0.40) | LPLLIPGLIPE | |
| SCHEMBL29691041 | 0.80 | LPL (0.40) | LPLLIPGLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-4653438-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4649081-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025045233-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-4463231-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024153208-A9 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2024-08-22 | — | — | WO | disclosed |
| EP-4413008-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024153208-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2024149819-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| EP-4392424-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023025832-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235864-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4054719-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4055028-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022060836-A1 | INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |